BeiGene Dirección

Dirección controles de criterios 2/4

El CEO de BeiGene's es John Oyler , nombrado en Jan 2010, tiene una permanencia de 14.25 años. compensación anual total es $18.05M, compuesta por 4.4% salario y 95.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.45% de las acciones de la empresa, por valor de €468.33M. La antigüedad media del equipo directivo y de la junta directiva es de 2.5 años y 4.3 años, respectivamente.

Información clave

John Oyler

Chief Executive Officer (CEO)

US$18.9m

Compensación total

Porcentaje del salario del CEO	4.6%
Permanencia del CEO	14.3yrs
Participación del CEO	3.4%
Permanencia media de la dirección	2.6yrs
Promedio de permanencia en la Junta Directiva	4.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de John Oyler en comparación con los beneficios de BeiGene?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$19m	US$871k	-US$882m
Sep 30 2023	n/a	n/a	-US$959m
Jun 30 2023	n/a	n/a	-US$2b
Mar 31 2023	n/a	n/a	-US$2b
Dec 31 2022	US$18m	US$800k	-US$2b
Sep 30 2022	n/a	n/a	-US$2b
Jun 30 2022	n/a	n/a	-US$2b
Mar 31 2022	n/a	n/a	-US$2b
Dec 31 2021	US$17m	US$740k	-US$1b
Sep 30 2021	n/a	n/a	-US$1b
Jun 30 2021	n/a	n/a	-US$1b
Mar 31 2021	n/a	n/a	-US$1b
Dec 31 2020	US$14m	US$696k	-US$2b
Sep 30 2020	n/a	n/a	-US$2b
Jun 30 2020	n/a	n/a	-US$1b
Mar 31 2020	n/a	n/a	-US$1b
Dec 31 2019	US$13m	US$675k	-US$949m
Sep 30 2019	n/a	n/a	-US$829m
Jun 30 2019	n/a	n/a	-US$665m
Mar 31 2019	n/a	n/a	-US$737m
Dec 31 2018	US$28m	US$650k	-US$674m
Sep 30 2018	n/a	n/a	-US$505m
Jun 30 2018	n/a	n/a	-US$243m
Mar 31 2018	n/a	n/a	-US$147m
Dec 31 2017	US$10m	US$515k	-US$93m

Compensación vs. Mercado: La compensación total de John($USD18.05M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD5.57M).

Compensación vs. Ingresos: La compensación de John ha aumentado mientras la empresa no es rentable.

CEO

John Oyler (55 yo)

14.3yrs

Permanencia

US$18,925,730

Compensación

Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
John Oyler	Co-Founder	14.3yrs	US$18.93m	3.45% $ 542.9m
Xiaobin Wu	President & COO	6yrs	US$11.00m	0.060% $ 9.4m
Xiaodong Wang	Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder	14.3yrs	US$4.42m	0.77% $ 121.5m
Julia Wang	CFO & Principal Financial Officer	2.9yrs	US$6.07m	0.0055% $ 869.7k
Chan Lee	General Counsel & Senior VP	1.8yrs	US$4.05m	0.0014% $ 217.4k
Wang Lai	Global Head of R&D	no data	US$7.32m	0.10% $ 16.0m
Titus Ball	VP & Chief Accounting Officer	less than a year	sin datos	sin datos
Liza Heapes	Head of Investor Relations	no data	sin datos	sin datos
Yang Ji	Chief Compliance Officer	less than a year	sin datos	sin datos
Yan Qi	Senior VP & Head of Public Affairs - Greater China	3.3yrs	sin datos	sin datos
Jason Radford	Senior Vice President of Strategy & Corporate Development	1.3yrs	sin datos	sin datos
Mark Lanasa	Senior VP & Chief Medical Officer for Solid Tumors	2.3yrs	sin datos	sin datos

2.6yrs

Permanencia media

53.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 49BA se considera experimentado (2.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
John Oyler	Co-Founder	13.6yrs	US$18.93m	3.45% $ 542.9m
Xiaodong Wang	Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder	8.3yrs	US$4.42m	0.77% $ 121.5m
Steven Young	Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board	3.1yrs	sin datos	sin datos
Michael Goller	Independent Non-Executive Director & Member of the Scientific Advisory Committee	9.1yrs	US$481.92k	0.0025% $ 390.7k
Donald Glazer	Independent Non-Executive Director	11.3yrs	US$480.80k	0.20% $ 30.9m
Corazon Sanders	Independent Non-Executive Director & Member of Scientific Advisory Committee	3.8yrs	US$501.55k	0.0013% $ 196.9k
Anthony Hooper	Independent Non-Executive Director	4.3yrs	US$513.15k	0.00057% $ 89.8k
Alessandro Riva	Co-Chairman of Scientific Advisory Committee & Independent Non-Executive Director	2.3yrs	US$491.67k	0.0012% $ 193.8k
Olivier Brandicourt	Independent Non-Executive Director	less than a year	sin datos	0% $ 0
Ranjeev Krishana	Independent Lead Director	9.6yrs	US$487.05k	0.0025% $ 390.7k
Margaret Han Dugan	Member of Scientific Advisory Board & Independent Non-Executive Director	2.3yrs	US$510.55k	0.0012% $ 193.8k

4.3yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de 49BA se considera experimentada (4.3 años de antigüedad promedio).

BeiGene Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

BeiGene, Ltd., Annual General Meeting, Jun 05, 2024

Co-Founder recently sold €7.0m worth of stock

Beigene, Ltd. Announces Board Changes

Beigene, Ltd. Announces Change of Chair of Audit Committee

President recently sold €1.6m worth of stock

Co-Founder recently sold €807k worth of stock

Recent updates

BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

BeiGene, Ltd., Annual General Meeting, Jun 05, 2024

New minor risk - Insider selling

Co-Founder recently sold €7.0m worth of stock

BeiGene, Ltd. to Report Q1, 2024 Results on May 11, 2024

BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

BeiGene, Ltd. Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

BeiGene, Ltd. to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

BeiGene, Ltd. Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Full year 2023 earnings released: US$8.45 loss per share (vs US$19.43 loss in FY 2022)

BeiGene, Ltd. Announces Adults Living with Chronic Lymphocytic Leukemia in Ontario and Quebec Now Have Access, Through Public Reimbursement, to BRUKINSA® (Zanubrutinib)

Beigene, Ltd. Announces Board Changes

Forecast to breakeven in 2026

BeiGene, Ltd. Announces FDA Approves Label Update for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BeiGene, Ltd. Receives European Commission Approval for BRUKINSA®? (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Third quarter 2023 earnings released: EPS: US$2.06 (vs US$5.39 loss in 3Q 2022)

Beigene, Ltd. Receives Positive Recommendation from Nice in U.K. for Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeli

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

Second quarter 2023 earnings released: US$3.64 loss per share (vs US$5.50 loss in 2Q 2022)

U.S. FDA Accepts Biologics License Application in First-Line Advanced ESCC

BeiGene, Ltd. Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA(R)

Beigene, Ltd. Announces Change of Chair of Audit Committee

New minor risk - Profitability

New minor risk - Shareholder dilution

New minor risk - Profitability

Now 22% undervalued after recent price drop

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$3.64 loss per share (vs US$5.51 loss in 2Q 2022)

Beigene Announces Positive CHMP Opinion for Tislelizumab as Treatment for Advanced or Metastatic ESCC

Beigene, Ltd. Announces FDA Acceptance of sNDA for Fifth Brukinsa(R) Indication

New minor risk - Shareholder dilution

BeiGene, Ltd. to Report First Half, 2023 Results on Aug 30, 2023

New minor risk - Shareholder dilution

BeiGene Highlights Significant Brukinsa® (Zanubrutinib) Data at 17th International Conference on Malignant Lymphoma

Pharmacyclics LLC Files Complaint Against Beigene, Ltd. and Beigene USA, Inc

BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress

Now 25% undervalued after recent price drop

BeiGene, Ltd. Announces Approval of BRUKINSA (Zanubrutinib) by Health Canada for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Announces Presentations At the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

President recently sold €1.6m worth of stock

Beigene, Ltd. Provides Update Regarding Recent Business Developments

First quarter 2023 earnings released: US$3.35 loss per share (vs US$4.24 loss in 1Q 2022)

Now 20% undervalued

Full year 2022 earnings released: US$19.43 loss per share (vs US$15.71 loss in FY 2021)

BeiGene Announces BRUKINSA Approved in the U.S. for Chronic Lymphocytic Leukemia

Brukinsa (Zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma in Great Britain by MHRA

BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List

Co-Founder recently sold €807k worth of stock

BeiGene, Ltd. Announces Center for Drug Evaluation of the China National Medical Products Administration Accepts Supplemental Biologics License Application

Co-Founder recently sold €674k worth of stock

BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab

Co-Founder recently sold €598k worth of stock

Beigene, Ltd.'S Brukinsa Demonstrated Superior Progression-Free Survival over Imbruvica (Ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker At ASH

Beigene to Present Final Pfs Results from Alpine Trial Demonstrating Superior Pfs for Brukinsa® Versus Imbruvica® in Late-Breaking Oral Session At Ash 2022

Beigene, Ltd. Announces Change of Co-Chair of Scientific Advisory Committee

BeiGene Receives European Commission Approval for Brukinsa® (Zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (Cll)

High number of new directors

Beigene, Ltd. Announces Brazil Approvals for Brukinsa® as A Treatment for Rare Blood Cancers

Third quarter 2022 earnings released: US$5.39 loss per share (vs US$4.46 loss in 3Q 2021)

Abbisko Therapeutics Co., Ltd. Completes First Patient Enrollment in Phase II Clinical Trial for Investigational Pan-FGFR Inhibitor ABSK091 in Combination with Anti-PD-1 Antibody Tislelizumab Developed by BeiGene, Ltd. in Urothelial Carcinoma

BeiGene Receives European Commission Approval for BRUKINSA(R) (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

BeiGene, Ltd. Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL

Beigene Announces Positive Topline Results from Final Progression-Free Survival Analysis of Brukinsa® (Zanubrutinib) Compared to Imbruvica® (Ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (Cll) Trial

Co-Founder recently sold €3.9m worth of stock

NICE Recommends Beigene’s BRUKINSA® (Zanubrutinib) for Patients with Waldenström’s Macroglobulinemia Who Have Had At Least One Treatment

Beigene, Ltd. Announces Appointment of Member of Compensation Committee